EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
Yahoo Finance · Jul 31, 2026 · Medicus Pharma Ltd. Warrant (MDCXW)
Medicus Pharma Ltd. (NASDAQ:MDCX) on Friday secured regulatory clearance from the United Arab Emirates Department of Health – Abu Dhabi for its PRECISION-E2 Phase 2a clinical study. The trial evaluates Teverelix in women with moderate-to-severe symptomatic endometriosis, an estrogen-dependent disease affecting roughly 10% of reproductive-age women globally. The trial marks a significant milestone in advancing a prospective genomics-guided precision medicine program designed to identify patients
Not investment advice. Cached headline, not a full reprint.